Vortioxetine is a new antidepressant which is recommended for the treatment of major depressive episodes in adults which have responded poorly to at least two antidepressants within the current episode.
The mechanism of action of vortioxetine is not fully understood but it is thought that it primarily modulates receptor activity through the inhibition of the SERT transporter. Vortioxetine is also thought to possess some additional therapeutic properties that make it particularly useful in patients with treatment-resistant depression
The results of several clinical trials have been promising, with vortioxetine demonstrating effectiveness at the initial and maintenance treatment for major depressive disorder. Furthermore, vortioxetine is generally well tolerated with a side effect profile similar to other serotonergic antidepressants but is associated with a significantly lower incidence of sexual dysfunction and weight gain.